Table 2.
Per-patient, per-month costs of treatment by TKI estimated from a cohort of US patients with chronic myeloid leukemia observed in Truven’s MarketScan claims database (2011–2012; 2013 $USD)
| Monthly treatment costs* | Median cost, $ | Mean cost (95% CI), $ |
|---|---|---|
| Imatinib (n = 2616) | ||
| Direct outpatient costs | 11.22 | 696.25 (565.65 to 826.86) |
| Direct inpatient costs | 0 | 1963.48 (440.88 to 3486.08) |
| Direct drug payments | 5032.50 | 4652.59 (4456.98 to 4848.20) |
| Dasatinib (n = 1284) | ||
| Direct outpatient costs | 103.57 | 700.97 (575.02 to 826.92) |
| Direct inpatient costs | 0 | 647.21 (155.45 to 1138.97) |
| Direct drug payments | 7944.80 | 6328.27 (5981.25 to 6675.29) |
| Nilotinib (n = 864) | ||
| Direct outpatient costs | 111.65 | 634.81 (477.65 to 791.97) |
| Direct inpatient costs | 0 | 365.26 (40.92 to 689.60) |
| Direct drug payments | 7636.96 | 6287.03 (5866.54 to 6707.52) |
* All data were extracted from Truven MarketScan using a sample of 397 patients (4764 patient-months). CI = confidence interval; TKI = tyrosine kinase inhibitor.